Across TCGA pan-cancer cohorts, DANCR Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated DANCR data layer compared with 26 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher DANCR Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DANCR expression acts as an unfavorable survival marker.
SARC are the cancer types where DANCR Mutation most reproducibly stratifies survival.